
Electromed (ELMD) Stock Forecast & Price Target
Electromed (ELMD) Analyst Ratings
Bulls say
Electromed Inc. has demonstrated significant financial growth, with homecare revenue increasing by 14.8% to $14.1 million, attributed to enhanced sales rep productivity and effective demand generation initiatives. The company has successfully expanded its presence in the domestic homecare market while also making strides in acute care and select international markets, as indicated by a remarkable rise in distributor sales by 41% and hospital sales by 52%. Although SG&A expenses rose by 17.2% due to investments in sales, marketing, and reimbursement, these expenditures reflect a strategic commitment to support ongoing growth and capitalize on market opportunities.
Bears say
Electromed Inc faces a negative outlook primarily due to margin compression, competitive headwinds, and decreased productivity among sales representatives, which collectively hinder its ability to achieve growth targets. Additionally, delays in the expansion of its Pain Management and Wound Care segments are expected to adversely affect anticipated growth rates and overall profit margins. The decline in share prices from a peak of $35.43 to around $18 further underscores investor concerns regarding the company’s financial stability and market position.
This aggregate rating is based on analysts' research of Electromed and is not a guaranteed prediction by Public.com or investment advice.
Electromed (ELMD) Analyst Forecast & Price Prediction
Start investing in Electromed (ELMD)
Order type
Buy in
Order amount
Est. shares
0 shares